Abstract: The distinction of a Spitz nevus from melanoma can be very difficult. Pathologists may disagree on whether a Spitzoid melanocytic proliferation is benign or malignant, or acknowledge uncertainty about the diagnosis. As long as melanoma is suspected or strongly considered, a clinical management plan is often adopted as if the patient had melanoma, which may include sentinel lymph node (SLN) biopsy for staging. The findings of the sentinel node may resolve the diagnostic controversy about the primary tumor, but there is also the risk for more diagnostic confusion, uncertainty, and errors. We review the arguments in favor and against SLN biopsy for patients with diagnostically controversial Spitzoid melanocytic tumors, summarize current experience, and illustrate diagnostic pitfalls. Although SLN biopsy provides prognostic information helpful for clinical trials, we caution against performing the procedure as a diagnostic adjunct.
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Over the following decades, the concept of a distinct variant of a melanocytic nevus evolved, and lesions classified by Sophie Spitz and others as ''juvenile melanoma'' or ''melanoma of childhood'' eventually came to be known as ''spindle and epithelioid cell nevus'' or ''Spitz nevus.'' [2] [3] [4] [5] [6] [7] [8] This type of nevus typically occurs in children, adolescents, and young adults [2] [3] [4] [5] [6] [7] [8] and is typically noted to be a dome-shaped symmetric and well-demarcated papule. Histologically, it has the silhouette of a benign nevus characterized by circumscription and symmetry. Cytologically, it is composed of large spindle and/or epithelioid melanocytes, often with abundant cytoplasm. Multinucleated melanocytes are common and there is usually evidence of maturation with depth. A number of secondary features, such as associated epidermal hyperplasia, dull pink globules (also known as ''Kamino''-bodies or eosinophilic globules) at the dermoepidermal junction, and superficial dermal telangiectasia are also frequently seen in junctional or compound's Spitz nevi. [2] [3] [4] [5] [6] [7] [8] Although the diagnosis of a Spitz nevus in a young patient is usually fairly straightforward for an experienced dermatopathologist, some tumors are difficult to classify as benign or malignant. [7] [8] [9] The diagnostically challenging lesions tend to have ''atypical,'' but not ''obviously malignant'' features. They may, for example, display a fairly symmetric silhouette, but lack eosinophilic globules, contain an occasional mitotic figure near the base of the lesion, and/or show no or only limited maturation with depth. The diagnostic problem is made evident by the poor interobserver agreement among and errors even by experts, 9 and by malpractice claims of lethal melanomas having been misdiagnosed as Spitz nevi. 10 The reluctance of many pathologists, be it out of fear of error and/or out of lack of faith in the reliability of morphologic criteria for this diagnostic problem, to commit to a definitive diagnosis when it comes to the evaluation of unusual/atypical Spitzoid melanocytic proliferations is reflected in the many different terms they use in avoiding a specific diagnosis, such as ''atypical Spitz tumor,'' ''borderline lesion,'' ''minimally deviant,'' or ''Spitzoid melanocytic tumor of uncertain malignant potential.'' 11, 12 Diagnostic uncertainty represents a troubling problem for patients, their relatives, and clinicians involved in their care. Decisions need to be made, but how can one confidently accept a treatment plan when one is not sure what to treat? Whenever the possibility of cancer is raised, it is a common reaction to address the worst possible scenario. When melanoma is suspected by at least one expert or an expert specifically says that a melanoma cannot be ruled out, surgical options and adjuvant therapy are not infrequently chosen by patients and their clinicians as if the patient had melanoma, including removal of the primary tumor and staging work-up. However, such an approach can be very problematic, particularly if a lesion is present in a cosmetically sensitive area.
SENTINEL LYMPH NODE BIOPSY FOR CONTROVERSIAL MELANOCYTIC TUMORS-THE PROPOSAL AND ITS RATIONALE
In a commentary on how to practically deal with diagnostically difficult melanocytic tumors, Kelley and Cockerell proposed in 2000 13 that, in addition to wide excision, sentinel lymph node (SLN) biopsy may be considered for patients, if their tumors, under the assumption they were melanomas, would make them eligible for this procedure (eg, measured 1 mm or more in thickness). This way, those patients who eventually turn out to have malignant melanomas, would not have been denied an option they would have been offered had melanoma been recognized earlier.
They also suggested that the SLN procedure provides an additional benefit. Its results may be of potential diagnostic value. If a patient with a primary melanocytic tumor with a controversial diagnosis (opinions were rendered both in favor and against malignant melanoma or no clear diagnosis was made) underwent a SLN biopsy, the presence of metastatic tumor deposits in the node would support the malignant nature of the primary tumor. Or, in other words, '' a melanocytic neoplasm that metastasizes is melanoma. '' 11 This rationale has been readily embraced by many physicians. Surgeons at many institutions have begun to perform SLN biopsies on patients with diagnostically ambiguous Spitzoid melanocytic tumors. They and their pathologists have claimed diagnostic successes [14] [15] [16] and have proudly reported about this strategy in articles entitled such as ''pediatric melanoma: confirming the diagnosis with sentinel node biopsy'' 14 or ''nodular malignant melanoma with Spitz nevuslike pathologic features finally confirmed by the pathologic features of the sentinel lymph node.'' 15 
CONFIRMING THE DIAGNOSIS OF MELANOMA BY LYMPH NODE FINDINGS
Confirming a diagnosis of cutaneous melanoma by a positive lymph node and/or the subsequent clinical course intuitively makes sense. This is how pathologists have historically recognized the malignant nature of many tumors, that is, by correlating the histologic features of a primary tumor with outcomes data. This is how many diagnostic or prognostic criteria were established. This is also how errors in diagnosis are revealed. Or in Drs Mones' and Ackerman's words: ''a nevus that metastasizes is a melanoma that was misdiagnosed originally. '' 11 One such unfortunate scenario is described and illustrated herein to emphasize that lymph node findings can indeed impact on the diagnosis of a primary skin tumor. It happened to a young girl who presented with a new papule on her knee at age 12. The biopsy of the lesion was reported as ''spindle and epithelioid cell nevus with atypical features'' by an experienced dermatopathologist. It showed pagetoid melanocytes and Kamino bodies (Fig. 1) . Three years after complete excision of the primary tumor with negative margins, the lymph node draining the site of this lesion became enlarged and was found to contain metastatic melanoma composed of dense sheets of mitotically active small epithelioid melanocytes (Fig. 2) , similar to a subpopulation of the primary tumor. The girl died 3 years later of metastatic melanoma.
Thus, when in the absence of any other known primary melanoma a Spitzoid melanocytic tumor is associated with metastatic melanoma in the lymph node draining the site where it was located, that tumor has to be the leading suspect for being the source of the metastasis, especially when its histologic features were (or in retrospect should have been) worrisome for melanoma.
SENTINEL LYMPH NODE FINDINGS FOR CONTROVERSIAL LESIONS-ARGUMENTS AGAINST IT AND CAVEATS
SLN mapping and biopsy has become a popular procedure for eligible patients with primary cutaneous melanoma. 17 Its supporters emphasize the superior staging and prognostication provided by the histologic analysis of the SLN. [17] [18] [19] The SLN procedure, however, has also opponents, for both its use in general surgical cancer care and in the work-up of patients with ambiguous tumor diagnoses. [20] [21] [22] [23] [24] The general criticism is directed at the failure of the procedure to improve the survival of the majority of patients undergoing it. [20] [21] [22] It is viewed as an unnecessary expense of no proven benefit outside of the context of clinical trials, but with definite risk of iatrogenic morbidity. 20 Additional criticism has been voiced against using the procedure for patients with uncertain primary tumor diagnoses, with the argument that the presence of melanocytes in a node per se does not constitute sufficient proof of the malignant nature of the primary tumor. [23] [24] [25] Although there should be no doubt about the malignant nature of a primary tumor with histologic features suspicious for melanoma, if the regional lymph node metastasis looks frankly malignant (dense sheets of pleomorphic, mitotically active tumor cells, with foci of necrosis) and replaces a significant part of the node, the issue is indeed not so straightforward when only small microscopic clusters of melanocytes are identified, and the tumor cells are cytologically bland or at least not frankly malignant. 24 It is in reference to the latter scenario that caution is warranted against classifying cutaneous melanocytic tumors based on SLN results. As data are lacking about the incidence and spectrum of histologic findings of melanocytes in lymph nodes draining the skin of Spitz nevi (or Spitzoid melanomas), attempts to interpret the significance of not frankly malignant microscopic melanocytic aggregates in the nodal parenchyma of patients with ambiguous Spitz tumors are speculative rather than scientific. 23, 24 It is important in this context to be reminded of a basic principle of pathology that the presence of tissue types normally foreign to lymph nodes within a node does not necessarily equate with a metastatic malignant process. 25 A lymph node may contain individual cells or foci of cell aggregates from the tissues of the anatomic region drained by the node. [25] [26] [27] [28] [29] [30] [31] [32] There are many examples of such occurrences. Among the more commonly found scenarios are incidental detections of breast or Mu¨llerian epithelial cells, and mesothelial cells. [25] [26] [27] [28] [29] [30] [31] [32] The most plausible explanation for such findings is mechanical transport of benign epithelial cells along lymphatic routes. [25] [26] [27] [28] [29] [30] [31] [32] A related phenomenon is the occurrence of benign metastasizing leiomyoma, 33, 34 which suggests that some tumors can travel to and grow at other sites without further dissemination and without major adverse sequelae to the host, defying a conventional classification of metastatic malignancy. Likewise, the term ''metastasizing Spitz nevus'' has been proposed with the suggestion that Spitz nevi/tumors may involve a regional lymph node, but (usually) do not spread beyond the regional nodal basin. 35 Such considerations are speculative and understandably controversial. 11, 23, 25 One may at least point out that the analogy with leiomyoma is a stretch. In benign metastasizing leiomyoma, the primary tumor is histologically unequivocally benign. On the other hand, published illustrations of ''metastasizing Spitz nevi'' show features that may be interpreted as melanoma. 11, 35 Nonetheless, the suggestion that melanocytes in lymph nodes may not necessarily be malignant is reasonable. In fact, pathologists have already acknowledged the occurrence of this phenomenon in reports about nodal melanocytic nevi.
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NODAL NEVOMELANOCYTES VERSUS METASTATIC MELANOMA
The occurrence of benign nodal melanocytic nevi was first documented in the English literature by Stewart and Copeland. 36 We have learned that such nevi are particularly common in lymph nodes draining melanomas associated with nevi. 40 Their presence in lymph nodes may be the result of aberrant melanocyte migration during development 39 or represent ''benign metastases'' (benign melanocytes transported within lymphatic fluid to regional lymph nodes after having been mechanically dislodged into lymphatics). 37, 40 How are benign nodal nevomelanocytes then distinguished from metastatic melanoma? A number of criteria have been proposed for this diagnostic issue [36] [37] [38] [39] [40] [41] [42] FIGURE 2. Metastatic melanoma in the regional lymph node draining the site of the tumor illustrated in Figure 1 . Sheets of small amelanotic epithelioid melanoma cells are present.
( Table 1 ). The first assessment addresses the location of the melanocytes. Nodal nevi tend to be only or primarily present in the fibrous tissue of a node (Fig. 3) , especially the capsule, but may also be seen in fibrous stroma elsewhere, such as in trabeculae or around small vessels. In contrast, metastatic melanoma is usually found within the lymph node parenchyma, often in the subcapsular sinuses, but also in paracortical and medullary regions of the node. Exceptions, however, exist. Melanoma may at times be found in the lymph node capsule (Fig. 4) or within a lymphatic channel of the capsule. Likewise, a nodal nevus may involve the lymph node parenchyma 42 (Figs. 5, 6). One may also find both metastatic melanoma and nodal nevus in the same lymph node (Fig. 7) .
The second critical parameter is cytology. When melanocytes in a lymph node are markedly atypical (eg, enlarged nuclei with prominent nucleoli) and mitotically active, they must represent melanoma. This is how a diagnosis of metastatic melanoma in the absence of a known primary is established. It is more difficult when there is no overt cytologic atypia (eg, small epithelioid melanocytes with no mitotic figures). Then a nevus needs to be more strongly considered, but melanoma remains a concern, as the cytology of some melanomas can be deceptively bland. In such cases, it is necessary to compare the cytology of the intranodal melanocytes with the invasive component of the corresponding primary melanoma (Fig. 6 ). If they are similar, and the primary tumor is an unequivocal melanoma, then the melanocytes in the node need to be interpreted as metastatic melanoma. If the melanocytes in the node are clearly different (bland compared with the atypical invasive primary tumor cells), then the nodal melanocytes represent a nodal nevus (Fig. 6) . Recognition of differences in the cytology is also critical to diagnose metastatic melanoma adjacent to a nodal nevus in the same node (Fig. 7) .
A third category of possible diagnostic value is the immunophenotype of the nodal melanocytes. [40] [41] [42] Although results from immunostains can aide in the diagnosis, they need to be balanced with the clinical and histologic findings. Staining of nodal melanocytes for gp100 (HMB-45) favors melanoma, 40 especially when the staining intensity is strong and all or the majority of intranodal melanocytes are homogeneously labeled.
However, one should not be dogmatic about the staining pattern. As is the case for cutaneous nevi, staining for HMB-45 can occur in benign nodal nevi and is per se An immunostain of nodal melanocytes for Ki-67 (MIB-1) may also be helpful 41 (Fig. 4) . A nodal nevus would be expected to lack any staining for Ki-67 or have only a very low (<5%) labeling index. On the other hand, labeling of more than 5% to 10% of nodal melanocytes would favor metastatic melanoma. Immunohistochemical studies for the assessment of nodal melanocytes are unfortunately least helpful when one needs them the most, that is, in the evaluation of small aggregates of melanocytes in the node lacking severe atypia. There is often not enough lesional tissue left for ancillary studies or solitary melanocytes may be One particular diagnostic problem deserves special attention. It is the occurrence of intraparenchymal nevus cells, because this phenomenon is underrecognized and clearly relevant for the assessment of SLNs of diagnostically ambiguous melanocytic tumors. 42 The most convincing (ie, least controversial) cases of intraparenchymal nodal nevi are incidental detections of nests and single cells of melanocytes in SLNs from patients with mammary carcinoma who never had melanoma before or after the lymph node biopsy (Fig. 5) . The same findings become much more challenging to interpret in a patient with known melanoma.
If cytologically bland intranodal melanocytes are associated with a well-developed intracapsular and/or intratrabecular nevus cell proliferation (Fig. 5) , pathologists tend to accept them as benign. However, there may not always be an intracapsular component (Fig. 6C) , or at least it may not be detectable depending on the plane of sectioning (Fig. 5B) . Thus, it is important for pathologists to realize that not all melanocytes located in the parenchyma of lymph nodes represent metastatic melanoma. Some are benign intranodal nevomelanocytes.
If indeed nodal nevi could derive from passive transport (or ''benign metastasis'') of dislodged melanocytic aggregates of benign cutaneous nevi, then there should be no reason why this phenomenon could not also be seen in association with Spitz nevi. 23 Likewise, it is conceivable that on occasion a Spitzoid nodal nevus may show a predominant intraparenchymal distribution pattern of melanocytes, thereby simulating metastatic Spitzoid melanoma. Needless to say, that such a case would be exceedingly difficult to diagnose with confidence by light microscopic analysis alone. 
EXPERIENCE OF CANCER CENTERS WITH PATIENTS UNDERGOING SENTINEL LYMPH NODE BIOPSY FOR DIAGNOSTICALLY CONTROVERSIAL SPITZOID TUMORS
A number of cancer centers have proceeded to offer SLN biopsies to patients with diagnostically controversial Spitzoid melanocytic tumors. [45] [46] [47] [48] [49] They have done this primarily to address patients' concerns. Most patients when told that pathologists do not know for sure what kind of tumor they have, but are worried about possible melanoma, accept a treatment and staging plan as if they had melanoma, which often includes SLN biopsy.
A significant number of such patients have been found to have a ''positive'' node, with intranodal melanocyte aggregates ranging from less than 1 mm to several millimeters in greatest dimension ( Table 2 ). The rates of positive SLNs ranged from 28.6% to 50%, with a mean of 37% when the results of all studies are combined. [45] [46] [47] [48] [49] Most patients who had a positive SLN were then subsequently cared for as having metastatic melanoma. Many of them underwent complete regional node dissection. Some were also given interferon.
What lesson, if any, can one draw from these studies? Some may argue that the results simply point to diagnostic deficiencies of pathologists and their flawed terminology of the primary tumors. At least in retrospect, one might say, those tumors are nothing other that melanomas that were either misdiagnosed or not fully recognized. 11 With this perspective, the high incidence of reported metastases is not unexpected given the thickness of the primary tumor and the young age of the patients. 49 
ARE DIAGNOSTICALLY CONTROVERSIAL SPITZOID MELANOCYTIC TUMORS WITH POSITIVE SENTINEL LYMPH NODE NOTHING BUT UNDERRECOGNIZED MELANOMAS?
If those atypical and diagnostically ambiguous melanocytic tumors with positive SLNs are simply misdiagnosed melanomas one would expect the subsequent clinical course of the affected group of patients to parallel that of patients with conventional melanomas. However, that does not seem to be the case. None of the patients with a primary ambiguous Spitz tumor and positive lymph node in the 5 published series died of metastatic melanoma to date. [45] [46] [47] [48] [49] However, the followup is limited (median 14 mo, mean 23 mo, range: 1 to 62 mo). [45] [46] [47] [48] [49] It is likely only a matter of time until at least a rare death of a patient with an ambiguous Spitz tumor and positive SLN will be reported. Nonetheless, overall there is a clear trend toward fewer clinical recurrences and longer recurrence-free survival in comparison to patients with conventional melanoma.
How can one reconcile the presence of thick primary tumors and high incidence of metastatic tumor deposits with a ''less aggressive'' clinical course? First, it is important to point out that a more favorable clinical course does not prove that the tumors are not malignant. A fact worth considering is that the majority of tumor deposits were small. Small tumor volume in the SLN has been associated with better prognosis even for conventional adult-type malignant melanomas. 50 On the other hand, the smaller the tumor volume the more difficult it is to distinguish nodal nevi from metastatic melanoma, which suggests another possible explanation: some of the reported cases with melanocytes found in the lymph node draining a diagnostically controversial Spitzoid melanocytic tumor may represent underrecognized patterns of nodal nevus components, that is, the ''metastatic tumors'' may be nevi misdiagnosed as melanoma. Although it is difficult to exclude a possible intranodal melanocytic nevus in a rare case of a reported microscopic cluster of less than 1 mm, we doubt that the majority of the reported ''positive'' SLNs of patients with ambiguous primary melanocytic tumors can be dismissed as unusual forms of nodal nevi, especially when the melanocytes are distributed in the node similar to metastatic melanoma and have cytologic features of melanoma (Fig. 8) . Furthermore, retrospective analysis of some of the tumors by comparative genomic FIGURE 8. Aggregates of atypical epithelioid melanocytes in the sentinel lymph node draining the site of a skin tumor, which had been interpreted as Spitzoid melanocytic tumor of uncertain malignant potential. The findings of the lymph node suggest metastatic melanoma. Some might consider that surgical intervention, the very fact that the positive SLN was removed, may have altered the clinical course and allowed for a more favorable outcome. 49 Although it is possible that SLN biopsy may be therapeutically beneficial for subgroups of patients, current evidence suggests that the removal of the SLN fails to improve melanoma survival. [19] [20] [21] [22] Patient age may also play a role. It is known that younger age is associated with a higher incidence of positive SLNs. [51] [52] [53] [54] However, a possible impact of age on prognosis and the value of prognostic parameters, including a positive SLN in young patients is less than straightforward. 54 Although young age is considered a favorable prognostic factor for melanoma patients, which may at least in part reflect the strength of the immune system, this advantage is best noted when young patients are compared with elderly individuals. 54 The possible effect of age on prognosis is more complicated among children, teenagers, and young adults. 51 On the basis of a recent study of patients from the National Cancer Data Base, children aged 1 to 9 years may have poorer overall survival compared with teenagers and young adults, probably largely due to more advanced disease stage at initial presentation. 51 On the other hand, patients younger than 20 years of age with localized invasive cutaneous melanoma seem to have better survival compared with young adults with thick primary tumors, suggesting that Breslow thickness may be less relevant prognostically in children and teenagers. 51 Another hypothesis worth considering is that not all melanomas are the same, and that tumors classified as ''atypical Spitz tumors'' or ''Spitzoid melanomas of childhood'' represent a biologically distinct, perhaps ''less aggressive'' melanocytic tumor or subset of melanomas. It remains to be seen to what extent such a subtype of melanoma or atypical Spitz tumor 55 can morphologically and/or molecularly be defined and reproducibly classified, as well as conceptually be supported by long-term followup studies. We believe that it is likely that many tumors currently reported as atypical Spitz tumors are a mixture of difficult to diagnose nevi and melanomas. Further studies are needed to address the hypothesis that some tumors may represent a biologically distinct ''intermediate'' subset in the spectrum of Spitzoid melanocytic proliferations as proposed by Barnhill.
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PROPOSAL FOR ENHANCED ANALYSIS OF THE PRIMARY TUMOR
After having presented views in favor of and against SLN biopsy, what then is our opinion about the role of this procedure in the management of patients with a diagnostically controversial Spitzoid melanocytic tumor? When a patient has a melanocytic tumor with an uncertain or controversial melanoma diagnosis, a discussion about patient care needs to address the implications of a possible melanoma diagnosis. This includes staging and management options currently available for melanoma, such as SLN mapping and biopsy. However, patients, or in the case of children, parents need to be informed that the role of the SLN procedure is not to settle diagnostic uncertainty. It is designed as a staging procedure for proven melanoma, not as a diagnostic adjunct. It can only be diagnostically useful, if the lymph node reveals frankly malignant tumor. In some cases, its results may only add to diagnostic uncertainty, when the pathologist cannot reliably distinguish benign or clinically insignificant nodal melanocytes from metastatic melanoma. 23 As the clinical care and prognostic outlook depends on the accuracy of the diagnosis of the primary tumor, it needs to be worked up as precisely as possible based on clinical, histologic, immunophenotypic, and/or molecular features (Fig. 9) . The first step is to analyze the tumor under the microscope using established criteria for the diagnosis of melanoma and its distinction from Spitz nevi. If conflicting criteria are present (some histologic findings favoring melanoma, some a Spitz nevus), and the diagnosis is difficult or uncertain, it is prudent practice to consult with experienced colleagues (Fig. 9) . This approach works in many cases and often leads to a practical consensus on how to proceed clinically, if the majority of experts favor a benign or malignant tumor, respectively. If uncertainty and/or controversy about the correct diagnosis persists, further exploration by CGH or fluorescence in situ hybridization (FISH) increase in the copy number of chromosome 11p, current evidence suggests that the odds for a malignant tumor are low enough that further care and management may be designed as for a patient with a probable nevus and not for probable melanoma. 56, 57 In our opinion, SLN biopsy should not be performed in this setting.
If on the other hand, CGH or FISH reveal chromosomal aberrations typically associated with melanoma, further management as for melanoma is recommended. If the tumor's features (Breslow thickness, Clark level, status of ulceration, mitotic rate) would make it eligible for SLN biopsy, if it was a melanoma, offering that procedure seems appropriate under the same rationale as for conventional adult-type melanoma.
Although the use of CGH and FISH data of melanocytic tumors for diagnosis and clinical care decisions is appealing, as it provides a less subjective test parameter, one needs to be cautious when one currently uses such information. Independent test validation by multiple laboratories has not been performed yet. Furthermore, more robust data on specificity and sensitivity are needed. Nonetheless, it seems reasonable to take results from such studies into consideration for a diagnosis because of their biologic plausibility (it makes sense to accept a melanocytic tumor with numerous chromosomal aberrations typically associated with melanoma as melanoma).
When CGH or FISH tests cannot be performed or the results are not unequivocal, a diagnosis needs to be made nonetheless on whether or not a Spitzoid melanocytic proliferation ''is'' a nevus or melanoma. If even after consulting a number of experienced colleagues, one is not sure what the lesion represents, it is best to admit that. Controversy or uncertainty seems preferable to an erroneous ''definitive'' diagnosis. The clinical dilemma, however, how to plan further clinical care and follow-up remains. Medical care decisions in such a situation when the diagnosis is uncertain can only be performed on a case-by-case basis between clinician and patient.
If a path is chosen to proceed as for possible melanoma, clinicians should be willing to modify their algorithm from what is currently recommended for unequivocal melanoma. For example, if a SLN is found to contain melanocytes of uncertain significance, we caution against proceeding with a complete lymph node dissection and believe that it is in the better interest of the patient not to have any further surgical intervention given the lack of survival benefit, but the risk of iatrogenic morbidity.
